Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Female Hypoactive Sexual Desire Disorder - Overview
Female Hypoactive Sexual Desire Disorder - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Female Hypoactive Sexual Desire Disorder - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Female Hypoactive Sexual Desire Disorder - Companies Involved in Therapeutics Development
Better Life Pharmaceuticals Inc
Dare Bioscience Inc
Emotiol Brain BV
EndoCeutics Inc
Fabre-Kramer Pharmaceuticals Inc
Ivix Ltd
Kuhnil Pharmaceutical Co Ltd
S1 Biopharma Inc
Female Hypoactive Sexual Desire Disorder - Drug Profiles
(buspirone hydrochloride + testosterone) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(sildefil citrate + testosterone) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gepirone hydrochloride ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KI-1120 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PGSN-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prasterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sildefil citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SIP-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Female Hypoactive Sexual Desire Disorder - Dormant Projects
Female Hypoactive Sexual Desire Disorder - Discontinued Products
Female Hypoactive Sexual Desire Disorder - Product Development Milestones
Featured News & Press Releases
Mar 09, 2020: Dare Bioscience presents positive Sildefil Cream, 3.6% data supporting further development for the treatment of female sexual arousal disorder
Dec 11, 2019: Dar? Bioscience announces alignment with the FDA on phase 2b study design and novel primary endpoint PRO instruments to support the continued clinical development of Sildefil Cream, 3.6%, a potential therapy for Female Sexual Arousal Disorder
Oct 28, 2019: Dare Bioscience and Strategic Science & Technologies announce presentation of positive findings from thermography clinical study of Sildefil Cream, 3.6 % in healthy women at the Sexual Medicine Society of North America Conference
Sep 12, 2019: Ovoca announces filing of marketing authorisation application with Russian Ministry of Health for BP-101
Jun 17, 2019: Dar? Bioscience announces positive results in Thermography feasibility study with Sildefil Cream, 3.6%, a potential therapy for female sexual arousal disorder
Apr 23, 2019: Ovoca Bio announced US and EU clinical development plans
Mar 25, 2019: Ovoca Bio Libicore (BP-101) meets primary/secondary endpoints in phase 3 trial for hypoactive sexual desire disorder ahead of time
Mar 18, 2019: Dare Bioscience to present update on Sildefil Cream at 31st Annual ROTH Conference
Jan 04, 2019: S1 Biopharma announces expanded alysis of phase 2a data on Lorexys for treatment of hypoactive sexual desire disorder based on PGIC scale to be presented at 2019 ISSWSH/ISSM joint meeting
Dec 20, 2018: S1 Biopharma granted patents for Lorexys in Europe and Asia for treatment of hypoactive sexual desire disorder
Jan 09, 2018: Emotiol Brain FSIAD Product Lybridos shows High Efficacy and Safety in Phase 2B Trials
Jan 09, 2018: Emotiol Brain’s FSIAD Product Lybrido shows High Efficacy and Safety in Phase 2B Trials
Nov 02, 2015: Nicolas Sitchon, CEO of S1 Biopharma, to Present at BIO-Europe 2015 Conference
Aug 20, 2015: S1 Biopharma Supports FDA Approval of First-Ever Treatment for Hypoactive Sexual Desire Disorder
May 01, 2015: Emotiol Brain Prepares for the Last Stage in Clinical Development of Medicines for Sexual Dysfunction in Women
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Female Hypoactive Sexual Desire Disorder, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development for Female Hypoactive Sexual Desire Disorder, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Female Hypoactive Sexual Desire Disorder - Pipeline by Better Life Pharmaceuticals Inc, H2 2020
Female Hypoactive Sexual Desire Disorder - Pipeline by Dare Bioscience Inc, H2 2020
Female Hypoactive Sexual Desire Disorder - Pipeline by Emotional Brain BV, H2 2020
Female Hypoactive Sexual Desire Disorder - Pipeline by EndoCeutics Inc, H2 2020
Female Hypoactive Sexual Desire Disorder - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2020
Female Hypoactive Sexual Desire Disorder - Pipeline by Ivix Ltd, H2 2020
Female Hypoactive Sexual Desire Disorder - Pipeline by Kuhnil Pharmaceutical Co Ltd, H2 2020
Female Hypoactive Sexual Desire Disorder - Pipeline by S1 Biopharma Inc, H2 2020
Female Hypoactive Sexual Desire Disorder - Dormant Projects, H2 2020
Female Hypoactive Sexual Desire Disorder - Discontinued Products, H2 2020